{"id":"NCT02558400","sponsor":"Aerie Pharmaceuticals","briefTitle":"Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","officialTitle":"A Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solution, 0.005% in Subjects With Elevated Intraocular Pressure","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-18","primaryCompletion":"2017-05-17","completion":"2017-06-30","firstPosted":"2015-09-24","resultsPosted":"2019-06-04","lastUpdate":"2019-06-04"},"enrollment":718,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Open-angle Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"PG324 Ophthalmic Solution 0.02%/0.005%","otherNames":[]},{"type":"DRUG","name":"Netarsudil (AR-13324) Ophthalmic Solution 0.02%","otherNames":[]},{"type":"DRUG","name":"Latanoprost Ophthalmic Solution 0.005%","otherNames":[]}],"arms":[{"label":"PG324 Ophthalmic Solution 0.02%/0.005%","type":"EXPERIMENTAL"},{"label":"AR-13324 Ophthalmic Solution 0.02%","type":"ACTIVE_COMPARATOR"},{"label":"Latanoprost Ophthalmic Solution 0.005%","type":"ACTIVE_COMPARATOR"}],"summary":"To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to Netarsudil (AR-13324) Ophthalmic Solution and Latanoprost Ophthalmic Solution.\n\nFollowing completion of the Month 12 study visit procedures, subjects will be offered the opportunity to participate in a 2-month observational (i.e., non-interventional) trial extension.","primaryOutcome":{"measure":"Intraocular Pressure (IOP)","timeFrame":"Primary efficacy endpoint measured for 3 months (data collected at 08:00, 10:00 and 16:00 hours at Day 15, Day 43 and Day 90)","effectByArm":[{"arm":"PG324 Ophthalmic Solution","deltaMin":24.84,"sd":3.316},{"arm":"AR-13324 Ophthalmic Solution 0.02%","deltaMin":24.81,"sd":3.335},{"arm":"Latanoprost Ophthalmic Solution 0.005%","deltaMin":24.59,"sd":2.914}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["32166538"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":238},"commonTop":["Conjunctival Hyperaemia","Instillation Site Pain","Cornea Verticillata","Eye Pruritus","Lacrimation Increased"]}}